Share on LinkedInShare on LinkedIn

ARTICLE · 07 MAY 2025

Spotlight On Upcoming Oral Arguments – May 2025

Finnegan, Henderson, Farabow, Garrett & Dunner LLP
Finnegan, Henderson, Farabow, Garrett & Dunner LLP
Contributor
Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Finnegan, Henderson, Farabow, Garrett & Dunner LLP is one of the world’s largest firms focusing on...

View firm profile
Explore more from Finnegan, Henderson, Farabow, Garrett & Dunner LLP

The following arguments will be available live to the public, both in-person and through online audio streaming.

United StatesIntellectual Property

The following arguments will be available live to the public, both in-person and through online audio streaming. Access information will be available by 9 AM ET each day of argument at: https://cafc.uscourts.gov/home/oral-argument/listen-to-oral-arguments/.

Wednesday, May 7, 2025, 10:00 A.M.

Bruker Cellular Analysis, Inc. v. Univ. of British Columbia, No. 23-2227, Courtroom 203, Panel F

Appellant Bruker petitioned for an inter partes review of Appellee University of British Columbia's ("UBC") patent. The Patent Trial & Appeal Board ("PTAB") instituted review of U.S. Patent No. 10,087,408 (the "'408 patent"). The '408 patent relates to culturing cells in a microfluidic device. Claim 1 of the '408 patent is a method claim. The last step of Claim 1—the step purportedly missing from the prior art—recites "selectively recovering the cell or a clonal population thereof." Four references were relevant to Bruker's obviousness challenges: Dimov, Park, Kovac, and Han.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from